Anorgasmy or anorgasmia is the inability to achieve normal orgasm. Although this condition occurs in both sexes, it is much more common in women and, along with a loss of sexual desire, is one of the most common symptoms of sexual dysfunction that occurs in the female. However, unlike in men where the inability to orgasm is almost exclusively a secondary effect of an underlying physical disorder, anorgasmia in women can be caused by a number of physical and psychological factors.
Furthermore, in both sexes anorgasmia can occur as a secondary effect of many of the commonly prescribed anti-depressant medications. The disorder is classified as being either primary or secondary. Primary anorgasmia exists when a sexually active woman has never been able to experience orgasm at any time in her life. Studies have revealed that 10-25% of all women have never been able to achieve orgasm, and as a result, suffer from primary anorgasmia.
Secondary anorgasmy, which is present in approximately one third of all women, occurs when a previously orgasmic woman has lost the ability to achieve normal orgasm. In PPOD syndrome patients anorgasmia is a common symptom occurring in both sexes. In male PPOD patients it is most frequently of the secondary type, usually having developed in association with erectile dysfunction. However, in the female PPOD patient, anorgasmy can be either primary, as a result of having developed the PPOD syndrome prior to becoming sexually active, or secondary as a result of having developed the PPOD syndrome later in life.
In the female PPOD syndrome patient, anorgasmia is often times found in association with other symptoms of sexual dysfunction such as dyspareunia, vulvodynia and loss of sexual desire or libido. In men, there may additionally be orchialgia and/or phallodynia. Fortunately, as is the case with most of the symptoms related to the PPOD syndrome, the symptom of anorgasmia is usually very responsive and effectively treated by PPOD therapeutic protocols. Refer to cases 4, 7, 10, 11, 12, 14 and 16 for the response of anorgasmia to PPOD syndrome therapeutic protocols.